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Abstract
Leukocyte adhesion deficiency type II (LAD II) is a rare disorder characterized by recurrent infections, persistent
leukocytosis, and severe mental and growth retardation. LAD II neutrophils are deficient in expression of selectin ligand
activity, and exhibit a correspondingly diminished ability to roll on endothelium and to traffic to inflammatory sites in vivo.
LAD II patients exhibit a deficiency in the expression of cell surface fucosylated glycan structures that include the H and
Lewis blood group determinants and the sialyl Lewis x epitope, yet the corresponding fucosyltransferase activities responsible
for synthesis of these structures are expressed at normal levels. The molecular defect in LAD II has been localized to the
pathway that synthesizes GDP-fucose from GDP-mannose. However, the two known component enzymes in this GDP-
fucose biosynthetic pathway are normal in sequence and in expression levels in LAD II cells. The genetic lesion in LAD II
that accounts for the generalized fucosylation defect in LAD II patients remains to be determined. ß 1999 Elsevier Science
B.V. All rights reserved.
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1. Introduction
During the 1980s, several reports described a
group of human patients su¡ering from a syndrome
of frequent bacterial infections, defective pus forma-
tion, and peripheral blood leukocytosis. Neutrophils
from a¡ected patients were abnormal in a variety of
adherence-related functions. The molecular basis of
this syndrome was demonstrated to be due to the
absent or de¢cient expression of the LFA-1
(CD11a/CD18; KLL2), Mac-1 (CD11b/CD18;
KML2), and p150/95 (CD11c/CD18; KXL2) adhesion
molecules on the surface of leukocytes. The L subunit
(CD18) is common to all three of these heterodimeric
L2-integrins; mutations were detected in the CD18
gene of these patients [1]. Anderson and Springer
suggested that this syndrome be named leukocyte
adhesion de¢ciency (LAD) with the terms ‘moderate’
to denote de¢cient expression of L2-integrins and ‘se-
vere’ to denote undetectable expression [2]. Recently,
variant forms of this LAD syndrome have been de-
scribed in which leukocyte L2-integrins are dysfunc-
tional [3,4].
In 1992, two unrelated boys were discovered with
an LAD-like clinical presentation of recurrent, non-
pyogenic infection and leukocytosis. However, neu-
trophils from these patients were found to have nor-
mal CD18 expression levels and function [5]. These
patients also exhibited marked growth delay, severe
mental retardation and other neurological manifesta-
tions, and numerous facial and skeletal abnormalities
not observed in LAD patients [5,6]. Both boys also
exhibited the rare Bombay phenotype, a de¢ciency in
red cell H blood group antigen. Moreover, neither
patient expressed the Lewis blood group antigens
(Le(a3b3)), nor did they secrete soluble blood
group active carbohydrate substance in their saliva
(non-Secretor phenotype). Since the H, Lewis, and
Secretor blood group antigens are all fucosylated oli-
gosaccharide antigens, de¢ciencies of these antigens
in these patients implied a global defect in fucose
metabolism. Because other fucosylated antigens, rep-
resented by the sialyl Lewis x (SLex) structure, are
expressed by leukocytes and are required for selectin-
dependent leukocyte adhesion and transmigration, a
fucosylation defect would also account for the in-
creased infections and defective pus formation in
these patients. Indeed, £ow cytometry analyses of
these patients’ neutrophils disclosed a nearly com-
plete de¢ciency of SLex expression [5,8]. On this ba-
sis, Etzioni et al. proposed the term leukocyte adhe-
sion de¢ciency type I (LAD I) for the previously
described de¢ciency in L2-integrins, and the term leu-
kocyte adhesion de¢ciency type II (LAD II) for the
two patients with leukocyte SLex de¢ciency [5]. Anal-
ysis of the LAD II pedigrees associated with these
two patients implies that the trait is inherited in an
autosomal recessive manner [7]. The highly consan-
guineous pedigrees of the LAD II patients leave open
the possibility that they may be homozygous for mu-
tant alleles at several loci, with the attendant possi-
bility that the abnormal morphological and neuro-
logical phenotype of these patients may be
consequent to mutations in genes that are distinct
from the one(s) relevant to SLex de¢ciency.
2. Leukocyte function
2.1. Neutrophil function
The leukocyte adhesion defect in the LAD II syn-
drome is best understood in the context of our cur-
rent knowledge of leukocyte adhesion and tra⁄cking
processes. Emigration of leukocytes from the blood-
stream is initiated when endothelial cell E- and P-
selectins interact with their leukocyte-borne, oligo-
saccharide-dependent counter-receptors. Under vas-
cular shear conditions, this leads to tethering and
rolling of the leukocytes on the endothelium. These
events place leukocytes in proximity to endothelial
cell-derived chemokines, thus activating the adhesive
properties of integrin molecules expressed on leuko-
cytes. Binding of activated leukocyte integrins to
their counter-receptor ICAM-1 on the endothelial
layer in turn promotes ¢rm adhesion of leukocytes.
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Leukocytes arrested on the lumenal surface of blood
vessels subsequently transmigrate across the endothe-
lial barrier to their extravascular destination. This
sequence of events is essential to the tra⁄cking of
leukocytes into sites of in£ammation. Similar events
are involved in the homing of lymphocytes to lym-
phoid tissues and sites of immune surveillance [9].
P-, E-, and L-selectins comprise a family of mem-
brane-bound proteins that mediate the capture and
rolling of leukocytes at the endothelium [10]. The ‘C-
type’ lectin domain present at the N-terminus of
selectin molecules binds in a calcium-dependent
fashion to carbohydrate ligands present on the leu-
kocyte surface (in the case of P- and E-selectin) and
on the endothelial surface (in the case of L-selectin)
[11]. While the precise carbohydrate structures of
these biologically-relevant selectin ligands have not
been determined de¢nitively, a great deal of evidence
indicates they are related to and at least partially
comprised of sialylated fucosylated lactosamines,
represented by the SLex tetrasaccharide (NeuAcK2,3-
GalL1,4[FucK1,3]GlcNAc) (Fig. 1) [12^14].
As noted above, analysis of LAD II neutrophils
disclosed a complete de¢ciency in expression of anti-
gen(s) recognized by the CSLEX-1 monoclonal anti-
body [5], which exhibits speci¢city for SLex as a sur-
rogate marker for E- and P-selectin ligand activity
[13]. Neutrophils from LAD II patients were subse-
quently demonstrated to be defective in binding to P-
and E-selectins. When interleukin-1L was used to
upregulate E-selectin expression on the surface of
cultured human umbilical vein endothelial cells (HU-
VEC), LAD II neutrophils bound very weakly to the
HUVEC, under conditions where adherence of con-
trol neutrophils was shown to be E-selectin-depend-
ent [5]. Similar results were obtained when tumor
necrosis factor was used to upregulate HUVEC ex-
pression of E-selectin [15]. Likewise, when P-selectin
expression on HUVEC was stimulated with hista-
mine, only a small amount of LAD II neutrophil
binding was detected. This residual binding could
be completely abolished by antibody against CD18
but not by anti-SLex [15]. Moreover, neutrophils
from LAD II patients were unable to bind to plastic
dishes coated with recombinant E-selectin or platelet-
puri¢ed P-selectin [15]. In contrast, adhesion of LAD
II neutrophils to phorbol myristate acetate (PMA)-
treated HUVEC was comparable to that of control
neutrophils. Since PMA-induced adhesion is largely
CD18-dependent, this observation, along with anti-
CD18 blocking experiments, con¢rmed that the L2-
integrin-dependent adhesive function of LAD II neu-
trophils is intact [15].
LAD II neutrophils also exhibit defects in L-selec-
tin-mediated adhesive interactions. Neutrophils incu-
bated under static conditions in vitro form aggre-
gates that may be detected and quantitated
microscopically or by £ow cytometry. This aggrega-
tion process is dependent on both L-selectin and L2-
integrins [16]. LAD II neutrophils exhibit defective in
vitro aggregation properties [17], even though L-se-
lectin expression levels are normal on these cells and
their integrin-dependent adhesive activities are nor-
mal [15]. These results therefore imply that the fuco-
sylation defect in these cells diminishes or eliminates
the activity of the L-selectin counter-receptors ex-
pressed by neutrophils. These observations are con-
sistent with recent reports that have implicated a
molecule termed P-selectin glycoprotein ligand-1
(PSGL-1) and its component fucosylated O-linked
oligosaccharides [18], as an important L-selectin li-
gand on neutrophils [19]. LAD II-derived vascular
endothelial cells have been used to determine if fu-
cosylation is a requirement for L-selectin ligands ex-
pressed by vascular endothelium (as opposed to a
molecularly-distinct class of L-selectin ligands ex-
pressed by the high endothelial venules in secondary
lymphoid organs). These studies demonstrate that
LAD II umbilical vein endothelial cells do not di¡er
from normal HUVEC in their ability to support neu-
trophil rolling at low shear forces, a condition under
which such rolling is thought to be L-selectin-de-
pendent [20]. These observations imply that fuco-
sylation does not contribute to the activity of vascu-
lar endothelial cell L-selectin ligands, and are
consistent with prior observations implicating that
these ligands may be largely comprised of heparan
sulfate proteoglycans [21,22].
The function of LAD II neutrophils has also been
studied in vivo. Intravital microscopy studies exam-
ined the ability of £uorescently-labeled LAD II neu-
trophils to roll on venular endothelium in rabbits in
which vascular endothelial E-selectin had been in-
duced with an intraperitoneal injection of IL-1L
[23]. The fraction of LAD II neutrophils that rolled
on the venule endothelial layer was reduced by 80%
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compared to normal donor neutrophils. Of the resid-
ual rolling LAD II neutrophils, most rolled at a high-
er velocity and over shorter distances with frequent
detachments. By contrast, LAD I neutrophils exhib-
ited normal rolling parameters. When the chemoat-
tractant leukotriene B4 (LTB4) was simultaneously
perfused, many control neutrophils stuck ¢rmly to
the endothelium while CD18-de¢cient LAD I neutro-
phils did not. LAD II neutrophils were also unre-
sponsive to LTB4, as expected for cells that are un-
able to roll e⁄ciently. However, when vascular £ow
was interrupted, LAD II neutrophils did adhere to
the endothelium, and migrated to the extravascular
space in response to LTB4 [23]. This ¢nding may
account for the di¡erence in clinical phenotype ob-
served between patients who have the severe form of
LAD I (undetectable CD18 with serious infectious
complications) and patients who have LAD II (un-
detectable selectin ligands with moderate infectious
complications). LAD II patients may have fewer in-
fectious complications than those with the severe
form of LAD I because LAD II neutrophils maintain
an ability to transmigrate under conditions of re-
duced shear force observed in the context of edema
and vascular stasis at in£ammatory sites.
The in vivo response of LAD II cells has also been
assessed by skin window and skin chamber tests [24].
These experiments involve abrading the skin with a
scalpel, and then covering the abrasion with a cham-
ber ¢lled with £uid (skin chamber) or with a cover-
slip (skin window). This is followed by quantitation
of leukocytes that emerge in the abraded area as a
measure of the ability of LAD II leukocytes to em-
igrate to a site of sterile in£ammation. The migration
of both neutrophils and monocytes was reduced in
LAD II patients in these tests, con¢rming the re-
quirement for fucosylated selectin ligands in the re-
cruitment of leukocytes to in£ammatory sites [24].
These experimental ¢ndings are in agreement with
the neutrophilia, impaired leukocyte rolling, and re-
duced tra⁄cking to in£ammatory sites observed in P-
and/or E-selectin null mice, and in mice made de¢-
cient in Fuc-TVII, the K(1,3)fucosyltransferase impli-
cated in selectin ligand synthesis [25^29]. Moreover,
these in vivo observations reinforce the notion that
there is a speci¢c sequence of adhesive events medi-
ating the interaction of leukocytes with endothelial
cells. These LAD II studies further substantiate the
important function of the selectins and their ligands
in initiating the transmigration process.
Some properties of LAD II neutrophils are not
easily explained by an absence of fucosylated selectin
ligands at the leukocyte surface, however. In partic-
ular, LAD II neutrophils show decreased migration
through agarose, both in the presence and absence of
chemotactic stimuli [5]. Since neutrophil migration in
this context is apparently independent of selectin li-
gand-dependent events, this observation implies that
functions related to intrinsic mobility or shape
change may also be a¡ected by the defect in LAD
II patients. Any hypothesis formulated to explain
such agarose motility assay defects must include a
consideration that other parameters of neutrophil
migration and function are normal. These include
phagocytosis of serum-opsonized zymosan, alteration
of surface markers in response to activation by
PMA, shape change in response to f-Met-Leu-Phe
(FMLP), and spreading on PMA-coated coverslips
[5,15]. Moreover, LAD II neutrophils migrate nor-
mally across a HUVEC monolayer towards the che-
moattractant FMLP, suggesting that selectin ligand-
independent motility is intact in LAD II neutrophils
[15]. These results are in agreement with the intra-
vital microscopy experiments in which LAD II neu-
trophils were observed to emigrate from the vascula-
ture when £ow was reduced [23]. The molecular basis
for an apparent agarose motility assay defect in LAD
II neutrophils is not known.
The results of neutrophil kinetic studies performed
in a LAD II patient are also di⁄cult to interpret.
The reduced ability of LAD II neutrophils to exit
the bloodstream to sites of in£ammation would be
predicted to lead to a prolonged survival time of
neutrophils in the vascular compartment with result-
ing neutrophilia, as has been observed in LAD I [30].
Indeed, P-selectin null mice exhibit marked neutro-
philia with reduced clearance of labeled neutrophils
[25,31]. However, while leukocytosis with prominent
neutrophilia is consistently observed in LAD II pa-
tients, LAD II neutrophils exhibit a reduced half-life
in vivo (3.2 h versus a mean of 7.8 þ 2.4 h in normal
controls) [24]. The reason for the apparent discrep-
ancy between the short intravascular neutrophil half-
life in LAD II patients and the prolonged half-life in
LAD I patients and in P-selectin (3/3) mice is not
clear. It has also been observed that recovery of la-
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beled neutrophils following injection (expressed as
the ratio of circulating neutrophils to total neutro-
phils) is markedly increased in an LAD II patient,
implying a reduction in the number of marginated
neutrophils [24]. In contrast, the marginal neutrophil
pool has been reported to be normal in both LAD I
and P-selectin de¢cient mice [31,32]. Clari¢cation of
these inconsistent observations and the elucidation of
the role of adhesion molecules in neutrophil turnover
and maintenance of the neutrophil marginal pool
awaits further study.
Marrow neutrophil production was observed to be
increased eight-fold in one LAD II patient [24]. This
observation is consistent with the hypothesis that
selectin-dependent adhesion processes may partici-
pate in the homeostatic control of neutrophil produc-
tion as implied by the altered hematopoiesis observed
in P/E-selectin double-de¢cient mice [27]. The mye-
loid/erythroid ratio in these mice is skewed 5-fold in
favor of myeloid precursors coincident with large
elevations of the hematopoietic cytokines interleu-
kin-3 and granulocyte/macrophage colony-stimulat-
ing factor [27]. Further study is necessary to clarify
the potential role of selectin^selectin ligand interac-
tions in regulating hematopoiesis.
2.2. Lymphocyte function
Although LAD II patients su¡er from recurrent
infections, their adaptive immune systems do not ap-
pear to be severely impaired. For example, an LAD
II patient has been shown to mount a normal pri-
mary antibody response, and a slightly elevated sec-
ondary response, following immunization with the
bacteriophage PX174. Normal isotype switching
from IgM to IgG was also observed in this study
[24]. The same patient demonstrated a particularly
robust antibody response to keyhole limpet hemo-
cyanin (KLH) [33]. The total number and subset dis-
tribution of lymphocytes in vivo as well as the pro-
liferation of T cells and natural killer cell activity in
vitro are also normal in LAD II [5,33].
The absence of ligands for the endothelial selectins
in LAD II would be expected to lead to severely
impaired recruitment of memory T-lymphocytes to
the skin, since the cutaneous lymphocyte antigen
(CLA), a fucosylated structure similar to SLex, is
believed to be important to this process [34]. To ex-
amine this issue, Kuijpers et al. used immunohisto-
chemistry to examine skin biopsies from an LAD II
patient before and after challenge with KLH [33].
Although CLA reactivity was undetectable on lym-
phocytes in the LAD II biopsy, the number of CD3+
cells (T cells) present in LAD II skin both before and
after KLH injection was comparable to that of con-
trol skin. This result implies that CLA is not essential
for homing of a signi¢cant fraction of CD3+ T-lym-
phocytes to skin and provides support for functional
redundancy in adhesion molecules involved in leuko-
cyte recruitment. In this regard, a distinct upregula-
tion of vascular cell adhesion molecule-1 (VCAM-1;
CD106) was noted in the skin of the LAD II patient,
both before and after stimulation with KLH. In light
of studies showing that K4-integrins are capable of
supporting leukocyte rolling [35,36], increased endo-
thelial cell VCAM-1 expression in LAD II patients
could represent a compensatory response on the part
of the endothelium to allow for selectin ligand-de¢-
cient leukocytes expressing K4-integrins to be cap-
tured under conditions of shear £ow. Although T
cells apparently can tra⁄c to the skin in LAD II, it
is worth noting that clinical signs of delayed type
hypersensitivity (DTH) such as redness and swelling
are greatly diminished in these patients [33]. Since the
vasodilation and edema present in the DTH response
are largely mediated by in£ammatory cytokines re-
leased by type I helper T cells (TH1), this suggests
either that this subset of T cells is not e⁄ciently
recruited to the DTH site in LAD II, or that the
e¡ector functions of the T cells are somehow altered
because of the absence of selectin^selectin ligand in-
teractions during extravasation. The former possibil-
ity is supported by studies implicating E- and P-se-
lectin-dependent adhesion events in tra⁄cking of
TH1 cells to sites of cutaneous in£ammation [37].
The latter possibility is supported by recent work
linking the engagement of selectin ligands to intra-
cellular signaling events in T cells [38]. The absence
of neutrophil selectin ligands in LAD II patients will
impair recruitment of these cells to DTH sites, in
turn contributing to the rather mild clinical signs of
DTH observed in LAD II patients.
More detailed studies on lymphocyte function in
LAD II are still needed to determine if subtle defects
in the adaptive immune response are present. Such
studies are important in light of observations made
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in L-selectin (3/3) and Fuc-TVII (3/3) mice. Lym-
phocytes from L-selectin null mice do not bind to
high endothelial venules (HEV) in peripheral lymph
nodes [39]. Likewise, Fuc-TVII (3/3) peripheral
lymph node HEV are de¢cient in L-selectin ligand
activity [29]. The de¢cits are accompanied by dimin-
ished lymphocyte homing and by hypocellular pe-
ripheral lymph nodes in the L-selectin- and Fuc-
TVII-de¢cient mice, and are due to the requirement
for adhesive interactions between the lectin domain
of L-selectin and endothelial-derived fucosylated li-
gands in lymphocyte homing. It remains to be deter-
mined if the LAD II phenotype includes defective L-
selectin-dependent lymphocyte homing to secondary
lymphoid organs with a corresponding compromise
of the adaptive immune system.
3. Molecular basis
3.1. ABO and Lewis blood groups
An important clue to uncovering the molecular
defect in the LAD II syndrome came from the ob-
servation that LAD II patients exhibit a rare blood
group phenotype, termed Bombay for the city where
it was ¢rst described. The Bombay phenotype is
characterized by a de¢ciency in the H, A, and B
blood group antigens (Fig. 1).
Synthesis of the ABO antigens is consequent to the
sequential action of a series of glycosyltransferases
(Fig. 2) [40]. The penultimate step in this synthetic
pathway is catalyzed by the K(1,2)fucosyltransferases
encoded by the H and Se blood group loci. This
synthetic step yields the H blood group antigen, a
fucosylated glycan required, in turn, for the actions
of the allelic glycosyltransferases encoded by the
ABO blood group locus. Individuals with the Bom-
bay phenotype have been thought to be homozygous
for null alleles at the H locus, and at the Se locus.
This notion has been con¢rmed by molecular analy-
sis of the H and Se loci in several pedigrees that
include individuals with the Bombay phenotype.
However, it is apparent that de¢ciency of the fuco-
syltransferase substrate GDP-fucose, previously re-
ported in cultured mammalian cell lines though not
yet found in humans, could also yield a Bombay
phenotype (Fig. 2).
The LAD II patients are also de¢cient in the Lewis
blood group antigens, which also correspond to fu-
cosylated glycans (Fig. 1). Again, molecular analysis
of the Lewis blood group locus in Lewis-negative
individuals, and in their relatives, has disclosed that
this phenotype is generally accounted for by homo-
zygosity for null alleles at the Lewis blood group
K(1,3/4)fucosyltransferase locus. However, as noted
above, a Lewis-negative phenotype would also be
observed in the context of a defect in the synthesis
or subcellular localization of GDP-fucose.
It was therefore initially proposed that the Bom-
bay, Lewis-negative phenotype of the LAD II pa-
tients could be accounted for by homozygosity for
null alleles at the H, Se, and Lewis blood group loci.
Fig. 1. Structures of the fucosylated antigens altered in the
LAD II syndrome. The minimal component monosaccharides
and their linkage arrangement, corresponding to each antigen,
are encompassed by an ellipse. R corresponds to glycolipid or
glycoprotein substructures that display these terminal oligosac-
charide moieties. These structures are assembled by addition of
their component fucose moieties to non-fucosylated precursors
through the actions of one or more fucosyltransferases, each of
which requires GDP-fucose as a substrate. For each antigen,
absence of the fucose moiety eliminates reactivity with mono-
clonal antibodies speci¢c for these determinants. The biosynthe-
sis of these structures has been reviewed [40].
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It was further proposed that nullizygosity at these
loci could be consequent to one or more large dele-
tions of the regions of chromosome 19 where these
genes have been localized, and that the other mani-
festations of the LAD II syndrome could be ac-
counted for by deletion of genes also eliminated by
such large scale chromosomal aberrancies [7]. How-
ever, cytogenetic analyses and family studies involv-
ing blood group typing implied that this hypothesis
was incorrect [7]. Strong evidence against this pro-
posal is also provided by studies demonstrating the
presence of normal activity of H locus encoded se-
rum K(1,2)fucosyltransferase and Lewis locus en-
coded salivary K(1,3/4)fucosyltransferase activity in
LAD II patients ([41]; B.W. Weston, J.B. Lowe, un-
published data). Similarly, the leukocyte SLex de¢-
ciency characteristic of LAD II patients is not due to
deletion or mutation of the two leukocyte K(1,3)fu-
cosyltransferase implicated in leukocyte SLex expres-
sion, since LAD II leukocytes maintain essentially
normal leukocyte K(1,3)fucosyltransferase activities
(B.W. Weston, J.B. Lowe, unpublished data). Con-
sidered together, these observations argue that the
biochemical defect in these patients localizes to a
pathway involving the synthesis or subcellular local-
ization of the fucosyltransferase substrate GDP-fu-
cose.
3.2. Fucose metabolism
The de novo biosynthesis of GDP-fucose involves
a three reaction pathway that is conserved through-
out evolution, from prokaryotes to humans (Fig. 3).
In the ¢rst reaction, GDP-D-mannose is converted to
GDP-4 keto-6-deoxy-D-mannose through the action
of the GDP-D-mannose-4,6-dehydratase enzyme [42^
44]. The next step involves the conversion of GDP-4
keto-6-deoxy-D-mannose to GDP-4-keto-6-deoxy-L-
galactose by a 3,5-epimerase. Finally, GDP-L-fucose
is formed through the action of a 4-reductase. The
Fig. 2. Biosynthesis of the H, A, and B blood group antigens. Symbols are as in the legend to Fig. 1. The biosynthesis of these struc-
tures has been reviewed [40]. The H antigen is a fucosylated structure assembled from type 2 glycan precursors (shown here) or from
type I precursors (not shown) via the action of two di¡erent K(1,2)fucosyltransferases. The H blood group K(1,2)fucosyltransferase is
expressed by erythroid progenitors and is responsible for red cell H structure synthesis. The Secretor blood group K(1,2)fucosyltrans-
ferase is expressed by epithelial cells lining the gastrointestinal, respiratory, and urogenital tracts, and some salivary glands, and is re-
sponsible for elaboration of soluble H blood group structures in body £uids. H structures are subsequently used as essential precur-
sors by the A or B blood group glycosyltransferases to form the A or B blood group antigens, respectively. Homozygosity for null
alleles at both the H locus and the Se locus (in individuals with the Bombay blood group phenotype) prevents synthesis of H struc-
tures. Absence of H structures prevents synthesis of A or B structures, regardless of an individual’s ability to express the A or the B
transferase. Absence of the fucosyltransferase substrate GDP-fucose will also lead to a de¢ciency of H blood group structure synthe-
sis.
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epimerase and reductase functions both reside within
a single polypeptide [45,46]. The mammalian epimer-
ase^reductase is also known as the FX protein, hav-
ing been originally characterized as an abundant er-
ythrocyte protein of unknown function. It appears
that an important site of regulation in this de novo
pathway is the 4,6-dehydratase, which is feedback
inhibited by the ¢nal product of the pathway,
GDP-fucose [47]. GDP-fucose is produced in the cy-
tosol by this three step pathway and is then moved
into the lumen of the Golgi apparatus by a speci¢c,
but otherwise uncharacterized, transport protein
[48,49]. Once in the Golgi, GDP-fucose serves as a
substrate for fucosyltransferases in the construction
of nascent complex carbohydrate molecules attached
to both proteins and lipids.
Cells are also capable of utilizing fucose in the
formation of GDP-fucose via an alternative cytosolic
pathway termed the ‘scavenger’ or salvage pathway
[50]. Cytosolic fucose may be derived from two sour-
ces. Extracellular fucose can be translocated to the
cytosolic compartment via one or more speci¢c plas-
ma membrane transporter molecules [51]. Alterna-
tively, fucose liberated by K-fucosidase activities op-
erative during glycoprotein degradative processes in
the lysosome may ¢nd its way into the cytosolic com-
partment through uncharacterized pathways. Cyto-
solic fucose may then be converted directly to
GDP-fucose by the sequential action of two enzymes
in the salvage pathway (Fig. 3). The ¢rst of these, L-
fucose kinase, forms fucose-1-phosphate [52,53]. The
second, GDP-L-fucose pyrophosphorylase (GDP-fu-
cose ‘synthase’), catalyzes a reversible synthesis of
GDP-fucose [54,55]. Thus, GDP-fucose synthesis
can be restored in cells with a defect in the conver-
sion of GDP-mannose to GDP-fucose, by growing
such cells in the presence of fucose and bypassing
the defect via this scavenger pathway [56]. Quantita-
tive studies in HeLa cells have indicated that most of
the GDP-fucose synthesized in normal cells is pro-
duced from GDP-mannose through the de novo
pathway whereas the scavenger pathway provides a
Fig. 3. Biosynthesis of GDP-fucose in mammalian cells. Two di¡erent pathways, involving cytosolic enzymes, lead to formation of
GDP-fucose. The constitutively active de novo pathway initiates with GDP-mannose. The salvage pathway initiates with free fucose,
delivered to the cytosol from extracellular sources (shown) or from intracellular (lysosomal) sources (not shown). GDP-fucose is then
transported into the Golgi lumen where it is utilized by fucosyltransferases (not shown), whose catalytic domains reside within the
Golgi lumen. See text for details.
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minor contribution to the intracellular GDP-fucose
pool [57].
3.3. Genetic lesion
Recent work has more speci¢cally localized the
defect in LAD II to the de novo pathway of GDP-
fucose biosynthesis. Culture of LAD II lymphoblas-
toid cells in fucose-supplemented media confers on
these cells the ability to bind the fucose-speci¢c lectin
Lotus tetragonobolus agglutinin. Similar results have
been obtained using umbilical cord ¢broblasts and
HUVEC from an aborted LAD II fetus [20]. These
experiments indicate that exogenously supplied fu-
cose can be incorporated by LAD II cells through
an intact scavenger pathway for GDP-fucose synthe-
sis, bypassing an apparent defect in the de novo
pathway. These observations also imply that GDP-
fucose transport into the Golgi lumen is intact in
LAD II cells, though the analyses completed to
date do not allow one to know if there is a quanti-
tatively subtle defect in this process that might con-
tribute in some way to the biochemical phenotype in
this disorder. Examination of the in vitro activities of
the de novo pathway in LAD II cell lines reveals a
defect in 4,6-dehydratase activity, but not in the epi-
merase-reductase (FX protein) activities [58]. Inter-
estingly, lysates from LAD II cells contain a signi¢-
cant de¢cit in dehydratase activity early during the
assay, but essentially normal speci¢c activity follow-
ing an apparent lag phase that is not evident in con-
trol lysates. Furthermore, LAD II dehydratase is in-
hibited by high concentrations of substrate (GDP-
mannose), whereas wild-type dehydratase activity is
not susceptible to such substrate inhibition but is
inhibited by GDP-fucose [47]. Although the 4,6-de-
hydratase reaction is clearly impaired in LAD II
cells, no mutations are found in the coding region
of the LAD II dehydratase loci and levels of dehy-
dratase protein in LAD II cells are equivalent to
levels in control cells [58]. The altered kinetics of
the dehydratase reaction suggest that the defect in
LAD II involves a yet to be discovered regulator of
the de novo GDP-fucose synthetic pathway. Further
studies, including biochemical analysis of the rela-
tively unexplored area of GDP-fucose transport in
LAD II cells, are needed to pinpoint the speci¢c
defect in LAD II.
4. Concluding remarks
Considering the importance of selectin^selectin li-
gand interactions in the control of microbial invasion
and in the regulation of the immune system, it is
somewhat surprising that the immune de¢ciency of
LAD II patients is so moderate, especially in com-
parison to LAD I patients. Indeed, a recent report
indicates that the clinical status of the LAD II syn-
drome may improve during maturation since the fre-
quency of infections in one LAD II patient has de-
clined to the point where prophylactic antibiotics are
no longer necessary [8]. Although this patient still
su¡ers from profound developmental delay, his
only persistent medical problem is severe periodonti-
tis. In this context, it is interesting to consider the
possibility that dietary fucose acting through the
scavenger pathway of GDP-fucose synthesis could
be responsible for a subclinical improvement in the
boy’s immunological status and his reduced inci-
dence of infections. Such a mechanism would be con-
sistent with the low, but detectable SLex expression
(2^3% of normal) in this LAD II patient [8].
The recognition that the scavenger pathway of
GDP-fucose synthesis is intact in LAD II cells in
vitro suggests that the selectin ligand de¢ciency in
these patients could be partially or completely cor-
rected by addition of fucose to their diet. However,
fucose treatment would potentially also lead to the
expression of the H blood group determinant and
potentially the A and/or B determinants as well, de-
pending on the ABO status of the patient. Because
patients with the Bombay phenotype, including LAD
II patients [7], possess high titers of IgM-class, com-
plement ¢xing antibodies against the A, B, and H
antigens, treatment with fucose would be predicted
to lead to an acquired autoimmune hemolytic ane-
mia, the severity of which would be expected to cor-
relate with the extent of phenotypic correction. This
circumstance might be prevented, in principle at
least, through e¡orts to tolerize the fetus against
the H, A, and B antigens in utero. Naturally, this
would require the identi¢cation of LAD II cases
early during fetal development. Because LAD II fetal
erythrocytes are H antigen-de¢cient, prenatal diagno-
sis of at-risk pregnancies is possible [59].
The non-immune defects in LAD II are of unclear
origin, but their existence raises the interesting ques-
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tion of what role, if any, fucose metabolism plays
during normal growth and development. Lex-related
structures have been shown to be inhibitory to the
growth of glial cells in vitro [60] ; a dysregulation of
cell proliferation in the central nervous system during
embryogenesis could contribute to the neurologic ab-
normalities in LAD II. In this regard, it will be in-
teresting to study the phenotype of mice with a tar-
geted disruption of either the GDP-mannose-4,6-
dehydratase locus or the FX locus. A careful analysis
of the embryologic development of such mice could
provide insight into the potential contribution of fu-
cosylated structures to formation of the nervous sys-
tem.
Much has been learned regarding LAD II since it
was ¢rst described less than a decade ago. Although
it is known that LAD II patients manifest a defect in
GDP-fucose biosynthesis, the exact nature of the ge-
netic lesion in LAD II remains unknown. Despite the
fact that the LAD II syndrome is extraordinarily
rare, study of this disorder has advanced our under-
standing of fucose metabolism, selectin^selectin li-
gand interactions, and leukocyte adhesion. Thus,
the investigation of LAD II, as with so many other
‘accidents of nature’, has contributed and will con-
tinue to contribute to our knowledge of basic proc-
esses relevant to a wide range of physiological and
pathological situations.
5. Note added in proof
A third LAD II patient, unrelated to the previ-
ously described LAD II patients, has recently been
identi¢ed [61]. Analysis of GDP-fucose biosynthesis
in this patient revealed no apparent abnormality [62].
This new LAD II patient may possess a molecular
defect distinct from the previously described LAD II
patients.
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